{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:03:27Z","timestamp":1789401807327,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003052","name":"MOTIE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108334","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:22:15Z","timestamp":1783351335000},"page":"108334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Loss of ETV4 triggers PPM1E downregulation and AMPK\u2013ULK1-dependent autophagy to promote intrinsic trametinib resistance in breast cancer"],"prefix":"10.1016","volume":"231","author":[{"given":"Xiaodong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hyeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-5873","authenticated-orcid":false,"given":"Ji Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2026.108334_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1470-2045(25)00730-2","article-title":"1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"27","author":"Global, regional, and national burden of breast cancer among females","year":"2026","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ijc.1571","article-title":"Estimates of the world-wide prevalence of cancer for 25 sites in the adult population","volume":"97","author":"Pisani","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.phrs.2026.108334_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108334_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1947601911412376","article-title":"Therapeutic strategies for targeting ras proteins","volume":"2","author":"Gysin","year":"2011","journal-title":"Genes. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm2438","article-title":"Ras oncogenes: split personalities","volume":"9","author":"Karnoub","year":"2008","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"34","key":"10.1016\/j.phrs.2026.108334_bib8","doi-asserted-by":"crossref","first-page":"20776","DOI":"10.1073\/pnas.2009137117","article-title":"Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma","volume":"117","author":"Lin","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"14","key":"10.1016\/j.phrs.2026.108334_bib9","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Hoeflich","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108334_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2026.108334_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102458","article-title":"MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis","volume":"110","author":"Musacchio","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111443","article-title":"Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer","volume":"41","author":"Kim","year":"2022","journal-title":"Cell. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib13","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1038\/s41598-025-90574-3","article-title":"The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma","volume":"15","author":"Katt","year":"2025","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.phrs.2026.108334_bib14","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-23-0833","article-title":"Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells","volume":"23","author":"Pham","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"5-6","key":"10.1016\/j.phrs.2026.108334_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/15384047.2021.1919004","article-title":"Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism","volume":"22","author":"Elbadawy","year":"2021","journal-title":"Cancer Biol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2026.108334_bib16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-21-3382","article-title":"BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I\/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma","volume":"28","author":"Mehnert","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108334_bib17","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.7150\/ijbs.62752","article-title":"Rapamycin and trametinib: a rational combination for treatment of NSCLC","volume":"17","author":"Sun","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108334_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003917","article-title":"MEK1\/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer","volume":"10","author":"Prasad","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108334_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-024-07551-z","article-title":"Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795\/uprosertib in patients with metastatic triple negative breast cancer","volume":"210","author":"Prasath","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.phrs.2026.108334_bib21","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/0008-5472.CAN-18-2861","article-title":"Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer","volume":"79","author":"Weisner","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12029-020-00556-z","article-title":"Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases","volume":"52","author":"Xavier","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010179","article-title":"The Dual Role of Autophagy in Cancer Development and a Therapeutic Strategy for Cancer by Targeting Autophagy","volume":"22","author":"Yun","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108334_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc3262","article-title":"Deconvoluting the context-dependent role for autophagy in cancer","volume":"12","author":"White","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108334_bib25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41420-025-02667-7","article-title":"Long non-coding RNAs and autophagy: dual drivers of Hepatocellular carcinoma progression","volume":"11","author":"Goyal","year":"2025","journal-title":"Cell. Death Discov."},{"issue":"10","key":"10.1016\/j.phrs.2026.108334_bib27","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240412","article-title":"Autophagy: a novel target in order to overcome drug resistance in pancreatic adenocarcinoma","volume":"15","author":"Amiri","year":"2025","journal-title":"Open. Biol."},{"key":"10.1016\/j.phrs.2026.108334_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.782877","article-title":"JY. Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration","volume":"12","author":"Degan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2026.108334_bib29","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19671","article-title":"Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors","volume":"6","author":"Mulcahy Levy","year":"2017","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41419-023-05592-8","article-title":"Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors","volume":"14","author":"Bhatt","year":"2023","journal-title":"Cell. Death Dis."},{"issue":"10","key":"10.1016\/j.phrs.2026.108334_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrm2249","article-title":"AMP-activated\/SNF1 protein kinases: conserved guardians of cellular energy","volume":"8","author":"Hardie","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.febslet.2010.01.017","article-title":"mTOR regulation of autophagy","volume":"584","author":"Jung","year":"2010","journal-title":"FEBS Lett."},{"issue":"18","key":"10.1016\/j.phrs.2026.108334_bib33","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.1074\/jbc.M900573200","article-title":"ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy","volume":"284","author":"Ganley","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108334_bib34","doi-asserted-by":"crossref","unstructured":"Roach P.J.. AMPK -> ULK1 -> autophagy. Mol Cell Biol. 2011;31(15):3082-3084.","DOI":"10.1128\/MCB.05565-11"},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","article-title":"AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism","volume":"1","author":"Kahn","year":"2005","journal-title":"Cell. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2026.108334_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.cell.2011.07.039","article-title":"Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop","volume":"146","author":"Yang","year":"2011","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib37","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.celrep.2015.10.011","article-title":"RACK1 Promotes Autophagy by Enhancing the Atg14L-Beclin 1-Vps34-Vps15 Complex Formation upon Phosphorylation by AMPK","volume":"13","author":"Zhao","year":"2015","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108334_bib38","article-title":"Comprehensive analysis of the functional and immunological significance of ETV4 in pan-cancer and its validation in digestive tumors","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12272-023-01427-4","article-title":"The role and application of transcriptional repressors in cancer treatment","volume":"46","author":"Park","year":"2023","journal-title":"Arch. Pharm. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/ng.3728","article-title":"Inactivation of Capicua drives cancer metastasis","volume":"49","author":"Okimoto","year":"2017","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.phrs.2026.108334_bib41","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI126366","article-title":"CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs","volume":"129","author":"Okimoto","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108334_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1416697","article-title":"Molecular and therapeutic advancements in Capicua (CIC)-rearranged sarcoma","volume":"12","author":"Ponce","year":"2024","journal-title":"Front. Cell. Dev. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108334_bib43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/BJ20101562","article-title":"ERK\/p90(RSK)\/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capic\u00faa","volume":"433","author":"Dissanayake","year":"2011","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.phrs.2026.108334_bib44","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/hep.29738","article-title":"Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis","volume":"67","author":"Kim","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trecan.2020.08.010","article-title":"Capicua in Human Cancer","volume":"7","author":"Kim","year":"2021","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2012.20","article-title":"Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition","volume":"1","author":"Pellecchia","year":"2012","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib47","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1038\/s41598-025-90731-8","article-title":"Identification of ETV4 as a prognostic biomarker and correlates with immune cell infiltration in head and neck squamous cell carcinoma","volume":"15","author":"Tang","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2026.108334_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/ol.2021.13159","article-title":"Knockdown of ETV4 promotes autophagy-dependent apoptosis in GBM cells by reducing the transcriptional activation of EMP1","volume":"23","author":"Wang","year":"2022","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cellsig.2010.08.010","article-title":"Ppm1E is an in cellulo AMP-activated protein kinase phosphatase","volume":"23","author":"Voss","year":"2011","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.phrs.2026.108334_bib50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.mito.2011.01.010","article-title":"The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis","volume":"11","author":"H\u00fcttemann","year":"2011","journal-title":"Mitochondrion"},{"issue":"2","key":"10.1016\/j.phrs.2026.108334_bib51","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1096\/fj.201801417R","article-title":"Tissue-specific regulation of cytochrome c by post-translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosis","volume":"33","author":"Kalpage","year":"2019","journal-title":"Faseb J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108334_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","article-title":"Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition","volume":"69","author":"Mirzoeva","year":"2009","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib53","first-page":"741","article-title":"Trametinib: A Targeted Therapy in Metastatic Melanoma","volume":"9","author":"Hoffner","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108334_bib54","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.phrs.2026.108334_bib55","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/14712598.2015.1026323","article-title":"Trametinib in the treatment of melanoma","volume":"15","author":"Thota","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"18","key":"10.1016\/j.phrs.2026.108334_bib56","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2026.108334_bib57","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","article-title":"MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701","volume":"11","author":"Chen","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.phrs.2026.108334_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116796","article-title":"Glutamine transporter inhibitor enhances the sensitivity of NSCLC to trametinib through GSDME-dependent pyroptosis","volume":"233","author":"Liu","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/TUB-220009","article-title":"Predictive biomarkers for response to trametinib in non-small cell lung cancer","volume":"44","author":"Parekh","year":"2022","journal-title":"Tumour Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108334_bib60","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40268-024-00491-5","article-title":"Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid Leukemia","volume":"24","author":"Quesnel-Valli\u00e8res","year":"2024","journal-title":"Drugs R. D."},{"key":"10.1016\/j.phrs.2026.108334_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156287","article-title":"SCD1 drives bladder cancer progression and trametinib sensitivity","volume":"277","author":"Zhang","year":"2026","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.phrs.2026.108334_bib62","article-title":"Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108334_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29468","article-title":"Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma","volume":"69","author":"Hanft","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108334_bib64","first-page":"334","article-title":"Phase II Trial of Trametinib and Panitumumab in RAS\/RAF Wild Type Metastatic Colorectal Cancer","volume":"20","author":"Alshammari","year":"2021","journal-title":"Clin. Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108334_bib65","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jnci\/djad232","article-title":"Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach","volume":"116","author":"Grynberg","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2026.108334_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115273","article-title":"Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway","volume":"408","author":"Dai","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108334_bib67","first-page":"1747","article-title":"Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression","volume":"8","author":"Adeyinka","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108334_bib68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1677\/JME-07-0165","article-title":"Phosphorylation at serines 104 and 106 by Erk1\/2 MAPK is important for estrogen receptor-alpha activity","volume":"40","author":"Thomas","year":"2008","journal-title":"J. Mol. Endocrinol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108334_bib69","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108334_bib70","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41420-021-00508-x","article-title":"ETV4 promotes breast cancer cell stemness by activating glycolysis and CXCR4-mediated sonic Hedgehog signaling","volume":"7","author":"Zhu","year":"2021","journal-title":"Cell. Death Discov."},{"issue":"6","key":"10.1016\/j.phrs.2026.108334_bib72","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13341","article-title":"ETV4\u2011mediated transcriptional activation of SLC12A5 exacerbates ferroptosis resistance and glucose metabolism reprogramming in breast cancer cells","volume":"30","author":"Wang","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib73","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neo.2019.04.006","article-title":"Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8\/A9 in breast cancer aggressiveness","volume":"21","author":"Chen","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2026.108334_bib74","article-title":"Oncogenic role and drug sensitivity of ETV4 in human tumors: a pan-cancer analysis","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108334_bib75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s43188-024-00233-4","article-title":"Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer","volume":"40","author":"Park","year":"2024","journal-title":"Toxicol. Res."},{"issue":"17","key":"10.1016\/j.phrs.2026.108334_bib76","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","article-title":"The double-edged sword of autophagy modulation in cancer","volume":"15","author":"White","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib77","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1080\/15548627.2018.1450020","article-title":"Mechanisms and context underlying the role of autophagy in cancer metastasis","volume":"14","author":"Dower","year":"2018","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.phrs.2026.108334_bib78","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjd.17333","article-title":"Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma","volume":"180","author":"Verykiou","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108334_bib79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2015.04.028","article-title":"Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K\/Akt signaling in human lung cancer cells","volume":"364","author":"Yao","year":"2015","journal-title":"Cancer Lett."},{"issue":"40","key":"10.1016\/j.phrs.2026.108334_bib80","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1038\/onc.2016.70","article-title":"AMPK promotes tolerance to Ras pathway inhibition by activating autophagy","volume":"35","author":"Sanduja","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.phrs.2026.108334_bib81","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective autophagy elicited by RAF\u2192MEK\u2192ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108334_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cells14070557","article-title":"The Assessment of the Effect of Autophagy Inhibitors-Chloroquine and 3-Methyladenine on the Antitumor Activity of Trametinib Against Amelanotic Melanoma Cells","volume":"14","author":"Stencel","year":"2025","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.phrs.2026.108334_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16172989","article-title":"Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?","volume":"16","author":"Elshazly","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:08:35Z","timestamp":1789398515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":83,"alternative-id":["S1043661826002495"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108334","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of ETV4 triggers PPM1E downregulation and AMPK\u2013ULK1-dependent autophagy to promote intrinsic trametinib resistance in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108334"}}